Genflow Biosciences plc (LON:GENF)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1.900
+0.050 (2.63%)
Feb 12, 2026, 4:59 PM GMT
Market Cap9.38M +25.3%
Revenue (ttm)n/a
Net Income-1.80M
EPS-0.00
Shares Out493.55M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume10,060,159
Average Volume3,242,137
Open2.040
Previous Close1.900
Day's Range1.750 - 2.300
52-Week Range0.550 - 2.700
Beta2.26
RSI46.65
Earnings DateMay 6, 2026

About Genflow Biosciences

Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology company that focuses on developing biological interventions aimed at tackling the effects of aging, slowing, and halting the aging process, as well as reducing the incidence of age-related diseases. Its lead drug candidate is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for in... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 5
Stock Exchange London Stock Exchange
Ticker Symbol GENF
Full Company Profile

Financial Performance

Financial Statements